MDR-RA Defining Clinical and Molecular Phenotypes of Multi-Drug Resistance in difficult to treat Rheumatoid Arthritis
- Coordinator
- Universita Humanitas, Italy
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €7.4m
- Total cost
- —
- Partners
- 25 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101155807
What the project is doing
In the project's own words, from its summary on CORDIS.
Rheumatoid Arthritis (RA) is the most common, chronic, inflammatory joint disease with a prevalence of about 1% of the adult population (22M patients worldwide and 7M in EU) and estimated to be responsible for 10,000 disability adjusted life years (DALY's) costing EU society €55B annually. Despite aggressive therapy, about a third of patients have to give up work within 5 years of disease onset mainly due to lack of response to multiple disease modifying anti-rheumatic drugs (DMARDs), multi-drug resistance (MDR).
Thus, the main objective of this proposal is to define the clinical and molecular phenotypes leading to MDR in RA patients to prevent when possible or, when not possible, optimise the management of these patients. MDR-RA is highly relevant to the program, as these patients are often disabled, unable to work and paying a high personal and societal burden. Moreover, MDR-RA is under-researched and the underlying pathobiological mechanisms for resistance remain unknown, while as we have no predictors of therapeutic response to any of currently available drugs, inevitably treatment is based on trial-and-error.
MDR-RA has the ambition of transforming care for these patients and deliver significant advances beyond the state-of-the-art methodologies, as for the first time, molecular pathology will be integrated into clinical, psychosocial, pain perception and imaging profiling in existing clinical cohorts to develop truly holistic predictive models for future clinical use (iCare-RA). The transformative potential of iCare-RA will be tested in a prospective randomised trial in comparison with routine standard of care, while its future implementation potential will be assessed through an early economic modelling.
Finally, a strong management and dissemination strategy will facilitate further advancing science in the field, beyond the duration of the project, and future adoption by patients, specialist professional bodies, policy makers and regulatory authorities.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Humanitas | Pieve Emanuele | Italy | Coordinator |
| Eutema Research Services GmbH | Wien | Austria | Participant |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Cliniques Universitaires Saint-Luc ASBL | Bruxelles / Brussel | Belgium | Participant |
| Aardex Group SA | Sion | Switzerland | Associatedpartner |
| European Alliance of Associations for Rheumatology | Zurich | Switzerland | Associatedpartner |
| HOCH Health Ostschweiz | St. Gallen | Switzerland | Associatedpartner |
| Universitat Basel | Basel | Switzerland | Associatedpartner |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Region Syddanmark | Vejle | Denmark | Participant |
| Fundacion Para La Investigacion Biomedica De Cordoba | Cordoba | Spain | Third party |
| Instituto De Salud Musculoesqueletica SL | Madrid | Spain | Participant |
| Servicio Andaluz De Salud | Sevilla | Spain | Participant |
| Humanitas Mirasole SpA | Rozzano (Mi) | Italy | Third party |
| Pluribus One SRL | Cagliari | Italy | Participant |
| Universita Cattolica Del Sacro Cuore | Milano | Italy | Participant |
| Universita Degli Studi Di Verona | Verona | Italy | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Diakonhjemmet Sykehus AS | Oslo | Norway | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Queen Mary University of London | London | United Kingdom | Participant |
| The University of Manchester | Manchester | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI